MyoKardia Inc. (NASDAQ:MYOK) shares traded up 7.6% during mid-day trading on Wednesday . The company traded as high as $22.29 and last traded at $22.21, with a volume of 62,787 shares trading hands. The stock had previously closed at $20.65.

A number of research analysts recently issued reports on the stock. Cowen and Company reissued a “buy” rating on shares of MyoKardia in a research note on Friday, May 13th. Wedbush reissued an “outperform” rating and issued a $22.00 price objective on shares of MyoKardia in a research note on Thursday, May 12th. Zacks Investment Research raised shares of MyoKardia from a “sell” rating to a “hold” rating in a research note on Thursday, April 28th. BMO Capital Markets assumed coverage on shares of MyoKardia in a research note on Wednesday, July 20th. They issued an “outperform” rating and a $28.00 price objective on the stock. Finally, Credit Suisse Group AG reissued a “buy” rating and issued a $20.00 price objective (up from $16.00) on shares of MyoKardia in a research note on Tuesday, July 12th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. MyoKardia presently has an average rating of “Buy” and a consensus price target of $23.50.

The firm’s 50 day moving average price is $17.07 and its 200 day moving average price is $12.51. The company’s market cap is $583.09 million.

MyoKardia (NASDAQ:MYOK) last released its earnings results on Tuesday, August 9th. The company reported ($0.37) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.33) by $0.04. The business had revenue of $3.55 million for the quarter, compared to analysts’ expectations of $3.55 million. The business’s revenue was up .0% compared to the same quarter last year. Equities research analysts expect that MyoKardia Inc. will post ($1.50) EPS for the current fiscal year.

MyoKardia, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in the development of therapies for treating cardiovascular diseases. The Company focuses on developing and discovering therapies for hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.